Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Takeda
Institut Bergonié
Elevation Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
Pfizer
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Stanford University
Amgen
Masonic Cancer Center, University of Minnesota
University of Kansas Medical Center
GlaxoSmithKline
Roswell Park Cancer Institute
GlaxoSmithKline
Amgen
Fox Chase Cancer Center
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Altor BioScience